Aprea Therapeutics Launches New Corporate Website - www.aprea.com
06 April 2020 - 10:00PM
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical
company focused on developing and commercializing novel cancer
therapeutics to reactivate mutant tumor suppressor protein, p53,
today announced that it has launched a new, redesigned website,
www.aprea.com. With an updated design, the new aprea.com web-site
offers easy-to-navigate functionality and a content-rich site
experience created to provide fulsome information on Aprea’s
scientific focus, strategy and progress as the leader in developing
important anti-cancer therapies to reactivate the tumor suppressor
protein, p53.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company
headquartered in Boston, Massachusetts with research
facilities in Stockholm, Sweden, focused on developing and
commercializing novel cancer therapeutics to reactivate mutant
tumor suppressor protein, p53. The Company’s lead product candidate
is APR-246 (eprenetapopt), a small molecule in clinical development
for hematologic malignancies, including myelodysplastic syndromes
(MDS) and acute myeloid leukemia (AML). APR-246 has received
Breakthrough Therapy, Orphan Drug and Fast Track designations from
the FDA for MDS, and Orphan Drug designation from the European
Commission for MDS, AML and ovarian cancer. For more information,
please visit the company website at www.aprea.com.
About p53 and APR-246 (eprenetapopt)
The p53 tumor suppressor gene is the most frequently mutated
gene in human cancer, occurring in approximately 50% of all human
tumors. These mutations are often associated with resistance
to anti-cancer drugs and poor overall survival, representing a
major unmet medical need in the treatment of cancer.
APR-246 (eprenetapopt) is a small molecule that has demonstrated
reactivation of mutant and inactivated p53 protein – by restoring
wild-type p53 conformation and function – and thereby induce
programmed cell death in human cancer cells. Pre-clinical
anti-tumor activity has been observed with APR-246 in a wide
variety of solid and hematological cancers, including MDS and
AML. Additionally, strong synergy has been seen with both
traditional anti-cancer agents, such as chemotherapy, as well as
newer mechanism-based anti-cancer drugs and immuno-oncology
checkpoint inhibitors. In addition to pre-clinical testing, a Phase
1/2 clinical program with APR-246 has been completed, demonstrating
a favorable safety profile and both biological and confirmed
clinical responses in hematological malignancies and solid tumors
with mutations in the TP53 gene.
A pivotal Phase 3 clinical trial of APR-246 and azacitidine for
frontline treatment of TP53 mutant MDS is ongoing. APR-246 has
received Breakthrough Therapy, Orphan Drug and Fast Track
designations from the FDA for MDS, and Orphan Drug designation from
the EMA for MDS, AML and ovarian cancer.
The Company may use, and intends to use, its investor relations
website at https://ir.aprea.com/ as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD.
Forward-Looking Statement Certain information
contained in this press release includes “forward-looking
statements”, within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, related to our clinical trials, regulatory
submissions and projected cash position. We may, in some cases use
terms such as “predicts,” “believes,” “potential,” “continue,”
“anticipates,” “estimates,” “expects,” “plans,” “intends,”
“targets,” “confidence,” “may,” “could,” “might,” “likely,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Our forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties. Any
or all of the forward-looking statements may turn out to be wrong
or be affected by inaccurate assumptions we might make or by known
or unknown risks and uncertainties. These forward looking
statements are subject to risks and uncertainties including risks
related to the success and timing of our clinical trials or other
studies, risks associated with the coronavirus pandemic and
the other risks set forth in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on
Form 10-K. For all these reasons, actual results and
developments could be materially different from those expressed in
or implied by our forward-looking statements. You are cautioned not
to place undue reliance on these forward-looking statements, which
are made only as of the date of this press release. We undertake no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
Source: Aprea Therapeutics, Inc.
Corporate Contacts:
Scott M. CoianteSr. Vice President and Chief Financial
Officer617-463-9385
Gregory A. KorbelVice President of Business
Development617-463-9385
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024